LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Buy” from Analysts

LivaNova PLC (NASDAQ:LIVN) has received an average rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $69.17.

LIVN has been the subject of several analyst reports. The Goldman Sachs Group began coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target for the company. Stifel Nicolaus raised their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird raised their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Edgestream Partners L.P. acquired a new stake in LivaNova during the 3rd quarter worth approximately $244,000. Verition Fund Management LLC raised its stake in shares of LivaNova by 47.4% in the third quarter. Verition Fund Management LLC now owns 11,542 shares of the company’s stock valued at $606,000 after acquiring an additional 3,710 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of LivaNova in the third quarter valued at $217,000. Martingale Asset Management L P purchased a new position in LivaNova in the third quarter valued at $617,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in LivaNova by 92.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,740 shares of the company’s stock worth $6,449,000 after purchasing an additional 58,807 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Down 2.4 %

Shares of LIVN opened at $52.32 on Friday. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47. The firm has a market capitalization of $2.84 billion, a P/E ratio of 124.57 and a beta of 1.01. The firm has a 50-day moving average price of $51.56 and a 200 day moving average price of $52.98. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.